XML 64 R35.htm IDEA: XBRL DOCUMENT
v3.21.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 40 Months Ended | 47 Months Ended | 87 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 27, 2020 USD ($) | Apr. 05, 2018 USD ($) | Sep. 30, 2020 USD ($) | Aug. 31, 2020 USD ($) | May 31, 2020 USD ($) | Apr. 30, 2020 USD ($) $ / shares shares | Mar. 31, 2020 USD ($) $ / shares | Feb. 29, 2020 USD ($) product_target | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Aug. 31, 2019 USD ($) | May 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | May 31, 2017 USD ($) | Jan. 31, 2014 USD ($) program | Mar. 31, 2021 USD ($) option product_target royaltyFee product | Mar. 31, 2020 USD ($) $ / shares | Dec. 31, 2020 USD ($) | Mar. 31, 2021 USD ($) milestone product | Mar. 31, 2021 USD ($) milestone | Mar. 31, 2021 USD ($) product milestone | Feb. 28, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 26,280,000 | $ 13,076,000 |  |  |  |  |
Other long-term liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,228,000 |  | $ 7,011,000 | $ 7,228,000 | $ 7,228,000 | $ 7,228,000 |
California institute for regenerative medicine agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funds due under the agreement |  |  |  |  |  |  |  |  |  |  |  | $ 8,000,000.0 |  |  |  |  |  |  |  |  |  |
Other long-term liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,600,000 |  | 6,400,000 | 6,600,000 | 6,600,000 | 6,600,000 |
California institute for regenerative medicine agreement | Research grants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,200,000 |  |  |  |  |  |
Novartis Institutes for BioMedical Research, Inc. | Recognition of license and stand-ready fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,200,000 | 0 |  |  |  |  |
Novartis Institutes for BioMedical Research, Inc. | Research services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,700,000 | 0 |  |  |  |  |
Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from collaborators |  |  |  | $ 75,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 75,000,000.0 |  |  |  |
Collaborative arrangement transaction price | $ 95,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee | 75,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement estimated reimbursable service costs | 20,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 64,700,000 |  | 70,900,000 | 64,700,000 | 64,700,000 | 64,700,000 |
Financial advisory fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,500,000 |  |  |  |
Percent of initial recognition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 | 0 |  |  |  |  |
Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of specified preclinical development clinical development and first commercial sale milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received | 420,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of commercial milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received | $ 300,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen MA, Inc. | Recognition of license and stand-ready fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,300,000 | 0 |  |  |  |  |
Biogen MA, Inc. | Research services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,100,000 | 0 |  |  |  |  |
Biogen MA, Inc. | Collaboration and license agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from collaborators |  |  |  |  | $ 125,000,000.0 |  |  | $ 125,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration received on transaction |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 204,600,000 |  |  |  |
Maximum milestone payment receivable |  |  |  |  |  |  |  | $ 2,370,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of product targets | product_target |  |  |  |  |  |  |  | 12 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of product targets selected | product_target |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional product targets | product_target |  |  |  |  |  |  |  | 9 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Target selection period |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum number of product targets replaced | product_target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 |  |  |  |  |  |
Financial advisory fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,000,000.0 |  |  |  |
Percent of initial recognition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% |  |  |  |
Portion of contract asset recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,100,000 |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 | 0 |  |  |  |  |
Biogen MA, Inc. | Collaboration and license agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research period |  |  |  |  |  |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen MA, Inc. | Collaboration and license agreement | Pre-approval milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment receivable |  |  |  |  |  |  |  | $ 925,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen MA, Inc. | Collaboration and license agreement | Sales-based milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment receivable |  |  |  |  |  |  |  | $ 1,450,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen MA, Inc. | Stock purchase agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 175,900,000 |  | 183,200,000 | 175,900,000 | 175,900,000 | 175,900,000 |
Number of shares issued in transaction (in shares) | shares |  |  |  |  |  | 24,420,157 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sale of stock, price per share (in dollars per share) | $ / shares |  |  |  |  |  | $ 9.2137 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration received on transaction |  |  |  |  |  | $ 225,000,000.0 |  |  |  |  |  |  |  |  |  |  |  | 204,600,000 |  |  |  |
Standstill restriction period |  |  |  |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Standstill restriction, ownership threshold percentage ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.00%
Agreement restriction, percentage of shares held |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00%
Voting provisions expiration period |  |  |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Voting provisions, ownership threshold percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.00%
Excess consideration received on transaction |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 79,600,000 |  |  |  |
Collaboration agreement, equity issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 145,400,000 |  |  |  |
Recognized portion of equity issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,900,000 |  |  |  |
Kite Pharma, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,288,000 | 7,219,000 |  |  |  |  |
Kite Pharma, Inc. | Recognition of license and stand-ready fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,159,000 | 6,227,000 |  |  |  |  |
Kite Pharma, Inc. | Research services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 129,000 | 992,000 |  |  |  |  |
Kite Pharma, Inc. | Collaboration and license agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement transaction price |  |  |  |  |  |  |  |  |  | $ 189,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement estimated reimbursable service costs |  |  |  |  |  |  |  |  |  | 39,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 75,300,000 |  | 81,400,000 | 75,300,000 | 75,300,000 | 75,300,000 |
Milestone payments received |  | $ 150,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial research term of agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |  |
Number of options to extend initial research term | option |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |
Extended research term of agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year |  |  |  |  |  |
Separate upfront fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |
Collaborative arrangement estimated reimbursable service costs for new research plan |  |  |  |  |  |  |  |  |  | 3,400,000 |  |  |  |  |  |  |  |  |  |  |  |
Revenues under agreement |  |  |  |  |  |  |  |  |  | $ 150,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Kite Pharma, Inc. | Collaboration and license agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  | 3,010,000,000.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent development - and sales-based milestone payments to be received |  | 1,260,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent development - and sales-based milestone payments to be received |  | $ 1,750,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pfizer Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments received |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,000,000.0 |  |  |  |  |  |  |  |  |
Revenues under agreement |  |  |  |  |  |  |  |  | $ 25,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Contract to perform for others, cumulative compensation earned |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000.0 |  |  |  |
Increase (decrease) in revenue |  |  |  |  |  |  | $ 2,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) in net loss |  |  |  |  |  |  | $ 2,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares |  |  |  |  |  |  | $ (0.02) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pfizer Inc. | Recognition of license and stand-ready fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 400,000 |  |  |  |  |
Pfizer Inc. | SB-525 and other products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 70,000,000.0 |  |  |  |  |  |  |  |
Pfizer Inc. | C9ORF72 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |  |
Collaborative arrangement transaction price |  |  |  |  |  |  |  |  |  |  |  |  | 17,000,000.0 |  |  |  |  |  |  |  |  |
Milestone payments received |  |  |  |  |  |  |  |  |  |  |  |  | 12,000,000.0 |  |  |  |  |  |  |  |  |
Agreement termination, term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 years |  |  |  |  |  |
Revenues under agreement |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000.0 |  |  |  |  | 5,000,000.0 |  |  |  |
Number of products approved | product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |
Number of milestones included in transaction price | milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |
Pfizer Inc. | Maximum | SB-525 and other products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential amount to be funded for achievement of specified commercialized and sales milestones |  |  |  |  |  |  |  |  |  |  |  |  |  | 266,500,000 |  |  |  |  |  |  |  |
Pfizer Inc. | Maximum | SB-525 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone revenue receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | 300,000,000.0 |  |  |  |  |  |  |  |
Pfizer Inc. | Maximum | Other products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone revenue receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | 175,000,000.0 |  |  |  |  |  |  |  |
Pfizer Inc. | Phase 3 clinical trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  | $ 30,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract to perform for others, cumulative compensation earned |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,000,000.0 |  |  |  |
Pfizer Inc. | Achievement of specified clinical development intellectual property and regulatory milestones | Maximum | SB-525 and other products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  |  |  | 208,500,000 |  |  |  |  |  |  |  |
Pfizer Inc. | Achievement of first commercial sale milestones | Maximum | SB-525 and other products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 475,000,000.0 |  |  |  |  |  |  |  |
Pfizer Inc. | Achievement of specified preclinical development clinical development and first commercial sale milestones | Maximum | C9ORF72 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000.0 |  |  |  |  |  |  |  |  |
Pfizer Inc. | Achievement of commercial milestones | Maximum | C9ORF72 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  |  | $ 90,000,000.0 |  |  |  |  |  |  |  |  |
Pfizer SB-525 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 134,000,000.0 |  |  |  |  |  |
Agreement termination, term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 years |  |  |  |  |  |
Revenues under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 55,000,000.0 |  |  |  |  |  |
Research service fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 79,000,000.0 |  |  |  |  |  |
Pfizer SB-525 | Recognition of license and stand-ready fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,200,000 |  |  |  |  |
Pfizer SB-525 | SB-525 and other products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 55,000,000.0 |  |
Number of milestones achieved | milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |
Number of products approved | product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Number of milestones included in transaction price | royaltyFee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Pfizer SB-525 | Milestone achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000.0 |  |  |  |  |
Sanofi |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,060,000 | 499,000 |  |  |  |  |
Agreement termination, term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 180 days |  |  |  |  |  |
Revenues under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |
Milestone revenue receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,000,000.0 |  |  | $ 6,000,000.0 | $ 6,000,000.0 | $ 6,000,000.0 |
Number of products approved | product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |
Number of research programs | program |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |
Increase (decrease) in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (2,200,000) |  |  |  |  |
Increase (decrease) in net loss |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,200,000 |  |  |  |  |
Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ (0.02) |  |  |  |  |
Sanofi | Recognition of license and stand-ready fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 227,000 | $ (729,000) |  |  |  |  |
Sanofi | Milestone achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 154,000 | (492,000) |  |  |  |  |
Sanofi | Research services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 679,000 | $ 1,720,000 |  |  |  |  |
Sanofi | Collaboration and license agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 93,300,000 |  |  |  |  |  |  |
Collaborative arrangement estimated reimbursable service costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 59,800,000 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 800,000 |  | $ 1,200,000 | 800,000 | 800,000 | $ 800,000 |
Revenues under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000.0 |  |  |  |  |  |  |
Number of milestones included in transaction price | milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |
Cumulative milestone achieved |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,300,000 |  |  | 7,300,000 | 7,300,000 | $ 7,300,000 |
Sanofi | Collaboration and license agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 276,300,000 |  |  |  |  |  |  |
Sanofi | Collaboration and license agreement | Milestone two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone revenue receivable |  |  |  |  |  |  |  |  | $ 7,500,000 |  |  |  |  |  |  | 7,500,000 |  |  | 7,500,000 | 7,500,000 | 7,500,000 |
Milestone revenue reversal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  | 100,000 | 100,000 | 100,000 |
Sanofi | Collaboration and license agreement | Milestone three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone revenue receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,500,000 |  |  | 13,500,000 | 13,500,000 | 13,500,000 |
Sanofi | Collaboration and license agreement | ST-40 Beta Thalassemia Phase 1 clinical trial milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments received |  |  |  |  |  |  |  |  |  |  | $ 6,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Milestone revenue reversal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  | 100,000 | 100,000 | 100,000 |
Cumulative milestone achieved |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,900,000 |  |  | $ 5,900,000 | $ 5,900,000 | $ 5,900,000 |
Sanofi | Collaboration and license agreement | Achievement of specified clinical development And regulatory milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 115,800,000 |  |  |  |  |  |  |
Sanofi | Collaboration and license agreement | Achievement of specified sales milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 160,500,000 |  |  |  |  |  |  |

X
- Definition Aggregate additional revenue recognition milestone method revenue eligible to receive. + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Agreement Termination, Term + References No definition available. + Details
Name: | sgmo_AgreementTerminationTerm
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Equity Issued + References No definition available. + Details
Name: | sgmo_CollaborationAgreementEquityIssued
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Number Of Additional Product Targets + References No definition available. + Details
Name: | sgmo_CollaborationAgreementNumberOfAdditionalProductTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Target Selection Period + References No definition available. + Details
Name: | sgmo_CollaborationAgreementTargetSelectionPeriod
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreements number of products approved under agreement. + References No definition available. + Details
Name: | sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value + References No definition available. + Details
Name: | sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Arrangement, Research Period + References No definition available. + Details
Name: | sgmo_CollaborationArrangementResearchPeriod
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Percent Of Initial Recognition + References No definition available. + Details
Name: | sgmo_CollaborativeAgreementPercentOfInitialRecognition
Namespace Prefix: | sgmo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld
Namespace Prefix: | sgmo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Cumulative Milestone Achieved + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementCumulativeMilestoneAchieved
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative arrangement estimated reimbursable service costs. + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Increase (Decrease) In Net Income (Loss) + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Increase (Decrease) In Revenue + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, License Fee + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementLicenseFee
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Maximum Milestone Payment Receivable + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Maximum Number Of Product Targets To Replace + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Milestone Revenue Reversal + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementMilestoneRevenueReversal
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Net Income (Loss) Per Share + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementNetIncomeLossPerShare
Namespace Prefix: | sgmo_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Number Of Milestones Achieved + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementNumberOfMilestonesAchieved
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Number Of Product Targets + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementNumberOfProductTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Number Of Product Targets Selected + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementNumberOfProductTargetsSelected
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Research Service Fees + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementResearchServiceFees
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage
Namespace Prefix: | sgmo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Standstill Restriction Period + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementStandstillRestrictionPeriod
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement transaction price. + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Voting Provisions Expiration Period + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage
Namespace Prefix: | sgmo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Contingent development and sales based milestone payments to be received. + References No definition available. + Details
Name: | sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Customer contract liability milestone payment eligible to receive. + References No definition available. + Details
Name: | sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Extended Research Term Of Agreement + References No definition available. + Details
Name: | sgmo_ExtendedResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Grant funding amount. + References No definition available. + Details
Name: | sgmo_GrantFundingAmount
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Initial research term of agreement. + References No definition available. + Details
Name: | sgmo_InitialResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments received. + References No definition available. + Details
Name: | sgmo_MilestonePaymentsReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone​ revenue receivable. + References No definition available. + Details
Name: | sgmo_MilestoneRevenueReceivable
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of clinical or regulatory milestones included in transaction price. + References No definition available. + Details
Name: | sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Options To Extend Initial Research Term + References No definition available. + Details
Name: | sgmo_NumberOfOptionsToExtendInitialResearchTerm
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of research program. + References No definition available. + Details
Name: | sgmo_NumberOfResearchProgram
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned + References No definition available. + Details
Name: | sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sale of Stock, Excess Consideration Received on Transaction + References No definition available. + Details
Name: | sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Separate upfront fee. + References No definition available. + Details
Name: | sgmo_SeparateUpfrontFee
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 + Details
Name: | us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSoldAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherLiabilitiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PhaseThreeClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sgmo_CollaborativeAgreementMilestoneAxis=sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |